2.4. Serological Investigation

The cat’s specific serological response against SARS-CoV-2 was investigated at Days 14 and 31 (see Figure 1) by means of two ELISA commercial kits, an electrochemiluminescence immunoassay (ECLIA) and plaque reduction neutralization test (PRNT).

Schematic representation of the clinical case events. The cat started presenting respiratory and gastrointestinal signs on Day 7. On Day 14 occurred the first veterinary examination (sample setting and thoracic radiographies) and the beginning of medical treatment administration. On Day 21, the cat no longer presented clinical symptoms. On Day 31, the second veterinary consult (sample setting and chest radiographies) was carried out. Specific serum antibodies were detected starting from Day 14 (ELISA, ECLIA and PRNT).

Feline Immunodeficiency Virus (FIV) was ruled out performing an immunochromatographic commercial KIT (SNAP FIV/FeLV Combo Test, IDEXX Europe, Hoofddorp, The Netherlands) on the cat’s serum.

The serological response against SARS-CoV-2 of the two veterinarians following the clinical case was investigated only on Day 31, through an ELISA commercial kit (ID.vet Innovative diagnostics, Grabels, France), ECLIA and PRNT.